Anti-PD1 antibody [NAT105],Abcam,AB52587
Anti-PD1 antibody [NAT105] (ab52587) is a mouse recombinant monoclonal antibody and is validated for use in Flow Cyt, ICC/IF, IHC-Fr, IHC-P and WB. Anti-PD1 antibody [NAT105] (ab52587) was first used in a scientific publication in 2007 and has been cited over 282 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [NAT105] (ab52587) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-PD1 antibody [NAT105] (ab52587) has 8 independent reviews from customers. Anti-PD1 antibody [NAT105] (ab52587) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µg) and larger sizes for subsequent scaling up experiments (100 ug and 1 mg). Conjugation-ready, carrier free format available for antibody clone NAT105 - ab201811 . Antibody clone NAT105 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, PE, Alexa Fluor ® 647, Alexa Fluor ® 555 ( ab220300 , ab220301 , ab220302 , ab279695 , ab280864 ). PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Mouse
Reactivity
Human
Application
WB, IHC-P, Flow Cyt, ICC/IF, IHC-Fr
Platform ID
BAB667868678
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 21276005, PubMed : 31754127, PubMed : 32184441, PubMed : 37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed : 21276005, PubMed : 26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed : 32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2 : following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed : 32184441).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 22658127, PubMed : 25034862, PubMed : 25399552). See full target information PDCD1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.